



Test Report/ Certificate of Analysis

Date of Report Jan 29, 2026
To: Resolve Peptides
From: AxisPharm, LLC
Certificate ID Number: 29Jan2026-012

Results reported by: Lab Technician
Ning Yang

Review/Approved by: 
QA Director
Dawei Yue

Sample Received: Date: 01/08/2026
Receiving Condition: ☒ Acceptable ☐ Other: _____
Storage Condition: ☐ Room temperature ☐ -20°C ☒ -80°C
☐ Other: _____

Method(s): Sample Name: GLP-1/GIP Dual Agonist (Tirzepatide) 10mg;
Batch: TIRZ-10-006-26, Label mg Claim: 10mg, EXP:
01/06/2028
LCMS


Procedure(s): Laboratory Activity Date: 01/23/2026
Results:

AxisPharm, LLC

Results only apply to tested Research Use Only samples within Test Report as received. Not for use in humans or animals. Analytical data apply only to the batch tested and do not indicate suitability for diagnostic or therapeutic use. Any unauthorized alteration, reproduction, or relabeling of this COA renders it invalid.



Test Report/ Certificate of Analysis



Sample Name	Net Weight Measured	MW (g/mol)	Detected	UV Purity (%)
GLP-1/GIP Dual Agonist (Tirzepatide) 10mg	9.8 mg	4813.53	2410.6 [M+2H], 1607.1 [M+3H]	99.4%

Salts and sugars that serves as fillers in injectables are not considered as impurities.

Conclusion: The product comes with GLP-1/GIP Dual Agonist (Tirzepatide) 9.8mg with purity 99.4%.

AxisPharm, LLC

Results only apply to tested Research Use Only samples within Test Report as received. Not for use in humans or animals. Analytical data apply only to the batch tested and do not indicate suitability for diagnostic or therapeutic use. Any unauthorized alteration, reproduction, or relabeling of this COA renders it invalid.